NECTIN4 and melanoma: Taking our findings together, we have shown that 1 NECTIN4 is expressed in melanoma patients and in melanoma cells, 2 NECTIN4 is upregulated in response to the acquisition of BRAFi resistance, and 3 melanoma cells are sensitive to MMAE (an anti-mitotic drug that is a component of ADCs).